{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:03:18Z","timestamp":1779908598514,"version":"3.53.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.pbb.2020.172878","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T11:33:32Z","timestamp":1582716812000},"page":"172878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats"],"prefix":"10.1016","volume":"191","author":[{"given":"Jiamei","family":"Lian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2020.172878_bb0005","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6","article-title":"Pharmacokinetics and tissue distribution of olanzapine in rats","volume":"20","author":"Aravagiri","year":"1999","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.pbb.2020.172878_bb0010","first-page":"225","article-title":"General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjogren\u2019s syndrome. 4th communication: effects on gastrointestinal, urinary and reproductive systems and other effects","volume":"52","author":"Arisawa","year":"2002","journal-title":"Arzneimittel-Forschung"},{"key":"10.1016\/j.pbb.2020.172878_bb0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/0269881115626349","article-title":"Betahistine decreases olanzapine-induced weight gain and somnolence in humans","volume":"30","author":"Barak","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pbb.2020.172878_bb0020","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1601-5037.2008.00326.x","article-title":"Comparison of the effects of pilocarpine and cevimeline on salivary flow","volume":"7","author":"Braga","year":"2009","journal-title":"Int. J. Dent. Hyg."},{"key":"10.1016\/j.pbb.2020.172878_bb0025","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fnins.2017.00643","article-title":"Molecular mechanisms of antipsychotic drug-induced diabetes","volume":"11","author":"Chen","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.pbb.2020.172878_bb0030","doi-asserted-by":"crossref","DOI":"10.4137\/CMT.S2131","article-title":"Cevimeline for the treatment of dry mouth in patients with Sjogren's syndrome","volume":"1","author":"Coaccioli","year":"2009","journal-title":"Clinical Medicine. Therapeutics."},{"key":"10.1016\/j.pbb.2020.172878_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2007.01.015","article-title":"A clinical study of the association of antipsychotics with hyperlipidemia","volume":"92","author":"de Leon","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pbb.2020.172878_bb0040","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1177\/0269881112449396","article-title":"Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model","volume":"26","author":"Deng","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pbb.2020.172878_bb0045","series-title":"Evoxac Capsules (cevimeline hydrochloride)","author":"FDA","year":"2005"},{"key":"10.1016\/j.pbb.2020.172878_bb0050","series-title":"U.S. FDA Center for Drug Evaluation and Research","article-title":"Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers","author":"FDA","year":"2005"},{"key":"10.1016\/j.pbb.2020.172878_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020571","article-title":"Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation","volume":"6","author":"Ferno","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2020.172878_bb0060","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archinte.162.11.1293","article-title":"Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial","volume":"162","author":"Fife","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pbb.2020.172878_bb0065","series-title":"Dubois\u2019 Lupus Erythematosus and Related Syndromes","first-page":"745","article-title":"Management of Sj\u00f6gren\u2019s","author":"Fox","year":"2019"},{"key":"10.1016\/j.pbb.2020.172878_bb0070","first-page":"1363","article-title":"Use of atypical antipsychotics in the elderly: a clinical review","volume":"9","author":"Gareri","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.pbb.2020.172878_bb0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cmet.2006.09.008","article-title":"Beneficial metabolic effects of M3 muscarinic acetylcholine receptor deficiency","volume":"4","author":"Gautam","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.pbb.2020.172878_bb0080","first-page":"565","article-title":"Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function","volume":"22","author":"Gilon","year":"2001","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.pbb.2020.172878_bb0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/026988110201600402","article-title":"Characterization of olanzapine-induced weight gain in rats","volume":"16","author":"Goudie","year":"2002","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pbb.2020.172878_bb0090","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2011.06.004","article-title":"Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model","volume":"131","author":"Hahn","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pbb.2020.172878_bb0095","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.psyneuen.2012.09.009","article-title":"Schizophrenia: metabolic aspects of aetiology, diagnosis and future treatment strategies","volume":"38","author":"Harris","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pbb.2020.172878_bb0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.psyneuen.2014.01.018","article-title":"Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats","volume":"42","author":"He","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pbb.2020.172878_bb0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1254\/jjp.78.373","article-title":"(+\/\u2212)-cis-2-methylspiro[1,3-oxathiolane-5,3\u2032-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors","volume":"78","author":"Iga","year":"1998","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.pbb.2020.172878_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.08.015","article-title":"M3 muscarinic receptor activation reduces hepatocyte lipid accumulation via CaMKK\u03b2\/AMPK pathway","volume":"169","author":"Jadeja","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pbb.2020.172878_bb0115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.schres.2018.03.016","article-title":"Dietary patterns and physical activity in people with schizophrenia and increased waist circumference","volume":"199","author":"Jakobsen","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pbb.2020.172878_bb0120","first-page":"488","article-title":"Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone","volume":"53","author":"Kaushal","year":"2012","journal-title":"Singap. Med. J."},{"key":"10.1016\/j.pbb.2020.172878_bb0125","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nm1201","article-title":"Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis","volume":"11","author":"Lam","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.pbb.2020.172878_bb0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.psyneuen.2014.06.010","article-title":"Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways","volume":"48","author":"Lian","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pbb.2020.172878_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104160","article-title":"Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment","volume":"9","author":"Lian","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2020.172878_bb0140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.phrs.2016.02.011","article-title":"Ameliorating antipsychotic-induced weight gain by betahistine: mechanisms and clinical implications","volume":"106","author":"Lian","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pbb.2020.172878_bb0145","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.lfs.2015.01.033","article-title":"Acute effects of oral olanzapine treatment on the expression of fatty acid and cholesterol metabolism-related gene in rats","volume":"128","author":"Liu","year":"2015","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2020.172878_bb0150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.phrs.2015.07.023","article-title":"Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKalpha-SREBP-1 and PPARalpha-dependent pathways","volume":"100","author":"Liu","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pbb.2020.172878_bb0155","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41598-017-02884-w","article-title":"Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pbb.2020.172878_bb0160","series-title":"The Attenuation of Second Generation Antipsychotic Induced Weight Gain in Adolescents and Young Adults Using Betahistine: A Double-Blind, Placebo-Controlled Trial","volume":"2015","author":"Maayan","year":"2015"},{"key":"10.1016\/j.pbb.2020.172878_bb0165","first-page":"1","article-title":"Effects of antipsychotic drugs on serum biochemical tests","volume":"3","author":"Makeen","year":"2017","journal-title":"Pyrex journal of biomedical research"},{"key":"10.1016\/j.pbb.2020.172878_bb0170","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14728222.12.9.1167","article-title":"Muscarinic acetylcholine receptors as therapeutic targets for obesity","volume":"12","author":"Maresca","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.pbb.2020.172878_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(97)01338-1","article-title":"Long-lasting salivation induced by a novel muscarinic receptor agonist SNI-2011 in rats and dogs","volume":"339","author":"Masunaga","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2020.172878_bb0180","first-page":"447","article-title":"A model for antipsychotic-induced obesity in the male rat","volume":"187","author":"Minet-Ringuet","year":"2006"},{"key":"10.1016\/j.pbb.2020.172878_bb0185","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.pnpbp.2018.01.023","article-title":"Meta regression: relationship between antipsychotic receptor binding profiles and side-effects","volume":"84","author":"Olten","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2020.172878_bb0190","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.archoralbio.2011.09.013","article-title":"Distinct effects of cevimeline and pilocarpine on salivary mechanisms, cardiovascular response and thirst sensation in rats","volume":"57","author":"Ono","year":"2012","journal-title":"Arch. Oral Biol."},{"key":"10.1016\/j.pbb.2020.172878_bb0195","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajp.2012.05.005","article-title":"Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: temporally based hypothesis","volume":"5","author":"Pai","year":"2012","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.pbb.2020.172878_bb0200","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"Federation of American Societies for Experimental Biology"},{"key":"10.1016\/j.pbb.2020.172878_bb0205","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1177\/0269881117722987","article-title":"Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment","volume":"31","author":"Reynolds","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pbb.2020.172878_bb0210","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.tem.2010.10.004","article-title":"Novel insights into the function of \u03b2-cell M3 muscarinic acetylcholine receptors: therapeutic implications","volume":"22","author":"Ruiz de Azua","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pbb.2020.172878_bb0215","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pbb.2020.172878_bb0220","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.archoralbio.2006.09.002","article-title":"Effects of cevimeline on salivation and thirst in conscious rats","volume":"52","author":"Sato","year":"2007","journal-title":"Arch. Oral Biol."},{"key":"10.1016\/j.pbb.2020.172878_bb0225","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bbr.2010.08.046","article-title":"Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone","volume":"216","author":"Shobo","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2020.172878_bb0230","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1007\/s00213-018-5079-1","article-title":"Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study","volume":"235","author":"Smith","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2020.172878_bb0235","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00213-005-0205-2","article-title":"A crossover study on lipid and weight changes associated with olanzapine and risperidone","volume":"183","author":"Su","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2020.172878_bb0240","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.psyneuen.2017.12.004","article-title":"Obesity exacerbates the acute metabolic side effects of olanzapine","volume":"88","author":"Townsend","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pbb.2020.172878_bb0245","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13181-010-0112-8","article-title":"Cevimeline (Evoxac \u00ae) overdose","volume":"7","author":"Voskoboynik","year":"2011","journal-title":"Journal of medical toxicology : official journal of the American College of Medical Toxicology"},{"key":"10.1016\/j.pbb.2020.172878_bb0250","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2165\/00003495-200868120-00006","article-title":"Cevimeline","volume":"68","author":"Weber","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.pbb.2020.172878_bb0255","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.schres.2009.09.034","article-title":"Sensitivity of the female rat to olanzapine-induced weight gain\u2013far from the clinic?","volume":"116","author":"Weston-Green","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pbb.2020.172878_bb0260","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbr.2010.10.039","article-title":"Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats","volume":"217","author":"Weston-Green","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2020.172878_bb0265","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.euroneuro.2011.09.003","article-title":"Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels","volume":"22","author":"Weston-Green","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2020.172878_bb0270","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s40263-013-0115-5","article-title":"Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor","volume":"27","author":"Weston-Green","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pbb.2020.172878_bb0280","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/35065604","article-title":"Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean","volume":"410","author":"Yamada","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2020.172878_bb0285","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neulet.2008.12.029","article-title":"Activation of muscarinic M-3 receptor may decrease glucose uptake and lipolysis in adipose tissue of rats","volume":"451","author":"Yang","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pbb.2020.172878_bb0290","series-title":"Sex Difference in the Association of Body Mass Index and BDNF Levels in Chinese Patients With Chronic Schizophrenia","first-page":"753","volume":"236","author":"Yang","year":"2019"},{"key":"10.1016\/j.pbb.2020.172878_bb0295","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1017\/S1461145713001697","article-title":"Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats","volume":"17","author":"Zhang","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2020.172878_bb0300","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.pnpbp.2014.02.003","article-title":"Olanzapine reduced brown adipose tissue thermogenesis and locomotor activity in female rats","volume":"51","author":"Zhang","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305719306409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305719306409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:37:10Z","timestamp":1758775030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305719306409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":59,"alternative-id":["S0091305719306409"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2020.172878","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2020.172878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172878"}}